When we analyzed the levels of the two known TAM receptor ligands, GAS6 and PROS1, in circulating CD4+CD11b- T cells, we found a significant increase of GAS6 level as well as the % of CD4+ T cell expressing GAS6 (Fig 1N–1P), but not differences in PROS1 expression in patients with HIMS compared with MS or HC (Fig 1Q–1S). This evidence concerns the gene CD4 and myeloid sarcoma.